A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults (MITIGATE)
Latest Information Update: 19 Jul 2023
At a glance
- Drugs Ethyl eicosapentaenoic acid (Primary)
- Indications COVID 2019 infections; Respiratory tract infections
- Focus Therapeutic Use
- Acronyms MITIGATE
- 14 Jul 2023 Status changed from active, no longer recruiting to discontinued.
- 07 Jan 2022 Status changed from recruiting to active, no longer recruiting.
- 13 Dec 2021 Planned number of patients changed from 16500 to 39600.